Clinical Trial Update: Afatinib in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification (ESCC-A01) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating afatinib in previously treated esophageal squamous cell carcinoma with EGFR overexpression or amplification.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Afatinib (afatinib)

Snippet

Sponsor: Peking University | Conditions: Esophageal Squamous Cell Carcinoma | Phase 2 | Status: UNKNOWN